tients with cancer in participating areas in the United States, covering 28% of the population and representative of national demographics. Our sample included adults aged 19 to 64 years with a first-time cancer diagnosis. Indiana University's institutional review board deemed this study to be nonhuman subjects research that did not require their approval or patient informed consent.
The outcome was the percentage of adults uninsured at diagnosis. We analyzed unadjusted changes in 2014, when the ACA health insurance exchanges and Medicaid expansion went into effect, compared with pre-ACA years 2010-2013. We repeated this analysis stratifying by (1) tumor location for the 5 most common types of nonskin cancer, (2) cancer stage, (3) race/ ethnicity, and (4) county poverty rate. We used difference-indifferences regression to assess whether changes in coverage were greater in states with Medicaid expansion than in nonexpansion states, with robust SEs clustered at the state level and adjusting for patient and county characteristics. All analysis was conducted using Stata software, version 14 (StataCorp). P values are 2-sided, and P < .05 indicates statistical significance.
Results | Data were obtained from the SEER Program for 858 193 nonelderly adults with new cancer diagnoses. Of these, 468 131 (54.55%) were women, and the mean (SD) age was 52.44 (9.66) years. The Limitations of our analysis include the availability of data from 13 states and 1 year of post-ACA data. Our results are descriptive, and our quasi-experimental Medicaid analysis is subject to potential time-varying confounders. Furthermore, other research indicates that uninsured patients are less likely to be diagnosed with cancer and more likely to be diagnosed at late stages.
3 Our finding that uninsurance was greater among those with distant disease in the pre-ACA and post-ACA periods is in line with research suggesting that uninsured patients may not seek care until their cancer has progressed. Although we provide novel evidence that fewer patients newly diagnosed with cancer were uninsured in the post-ACA period, our analysis did not separate the effects of gains in coverage among patients who would have been diagnosed in the absence of the ACA from changes in the number of diagnoses resulting from increased coverage. Future research should examine effects of coverage on cancer diagnoses, treatment, and outcomes. Policy changes that reduce Medicaid funding or weaken protections for individuals with preexisting conditions could be particularly harmful for patients with cancer.
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Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease
Von Hippel-Lindau (VHL) disease is a familial cancer syndrome caused by a germline mutation in the VHL tumor suppressor gene (OMIM 193300). 1 The prevalence of pancreatic neuroendocrine tumors (PNETs) in VHL disease ranges from 9% to 17% and is characterized by a better prognosis compared with sporadic PNETs. 2,3 Several risk factors for PNET metastasis in VHL disease have been reported 4 but have not been validated. We conducted a prospective study (NCT00062166) to evaluate the natural history of VHL disease-associated pancreatic lesions to determine what factors were associated with PNET phenotype and prognosis.
Methods | Patients were enrolled from January 1, 2010, to January 1, 2017, based on the following eligibility criteria: age of 12 years or older, a diagnosis of VHL disease based on germline VHL mutation or clinical criteria, 5 and a pancreatic manifestation of VHL disease. Pancreatic protocol (2-mm section) abdominal computed tomography and pelvis computed tomography with intravenous contrast material were performed annually or every 2 years in patients with solid or cystic pancreatic lesions, respectively. Each imaging study was assessed by at least 2 independent reviewers. The criteria for surgical resection of pancreatic solid lesions were reported previously.
2 Disease-free interval and progression-free interval were defined as the time from inclusion without PNET and with no tumor growth (>5 mm and >20%), respectively. Patients diagnosed with VHL disease underwent genetic testing for mutations in the 3 coding exons and exon-intron boundaries of the VHL gene and for partial or complete deletion or duplication of the VHL gene in Clinical Laboratory Improvement Amendments-approved laboratories.
6 This study was approved by the institutional review board of the National Cancer Institute, and written informed consent was obtained from all patients enrolled in the study. All data were deidentified. (Table) .
Patients with a greatest tumor diameter less than 1.2 cm had a 100% negative predictive value for developing metastasis and requiring a surgical intervention during follow-up, whereas patients with a tumor diameter greater than 3.0 cm had a high risk of metastatic disease on univariate (hazard ratio [HR], 8.6; 95% CI, 2.1-34.9; P = .003) and multivariable analyses (HR, 8.6; 95% CI, 1.7-43.2; P = .009).
Among patients with a PNET diameter of 1.2 cm or greater and 3 cm or less, only those with a VHL missense mutation developed metastatic disease during follow-up (5 [12.5%] vs 0 patients with missense vs other type of VHL gene mutation; logrank test, P = .04). Patients with a VHL missense mutation had a higher rate of requiring a surgical intervention compared with other mutation types(16 [40.0%] with missense vs 5 [16.1%] with other VHL gene mutation type; log-rank test, P = .04), and patients with a VHL gene mutation located in exon 3 vs exon 1 or 2 had a higher rate of requiring a surgical intervention during follow-up (13 [44.8%] vs 8 patients [23.5%], P = .02). Patients with a missense VHL mutation or any mutation type in exon 3 had a higher rate of surgical intervention compared with other VHL genotypes on univariate (HR, 9.2; 95% CI, 1.2-68.7; P = .03) and multivariable analyses (HR, 8.8; 95% CI, ; P = .04).
Discussion | Our study findings support an evidence-based algorithm for risk stratification and surveillance of patients with VHL-associated pancreatic lesions (Figure) . Such an approach would provide precision medicine for patients with VHL disease-associated pancreatic lesions based on VHL genotype and tumor size. These results should be validated in future studies because of the rate of metastatic disease observed in our cohort.
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